NASDAQ:AVR Anteris Technologies Global Q3 2026 Earnings Date & Estimates $6.23 -0.22 (-3.41%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more. Anteris Technologies Global is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 17, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 17, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Anteris Technologies Global in Q3 2026Anteris Technologies Global is expected to post earnings of -$0.3078 per share on revenue of $2.75 million. In the same quarter a year earlier Anteris Technologies Global reported -$0.62 per share on revenue of $0.43 million. Anteris Technologies Global last reported on August 11, 2026, posting -$0.30 per share and missing the -$0.2073 consensus estimate. Anteris Technologies Global has beaten the consensus EPS estimate in 0 of its last 4 quarters.Consensus EstimatesConsensus EPS-$0.3078Expected Revenue$2.75 millionPrior-Year EPS-$0.62Prior-Year Revenue$0.43 millionExpected Revenue Growth+541.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.30 (Missed by -$0.0927)Last Quarter Revenue$1.01 millionEPS Beat Rate0 of last 4 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Anteris Technologies Global Q3 2026 Earnings FAQ When does Anteris Technologies Global report Q3 2026 earnings? Anteris Technologies Global (NASDAQ:AVR) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Anteris Technologies Global's Q3 2026 earnings call? Anteris Technologies Global's Q3 2026 earnings conference call is scheduled for Tuesday, November 17, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Anteris Technologies Global? Analysts expect Anteris Technologies Global to post earnings of -$0.3078 per share for Q3 2026. How much revenue is Anteris Technologies Global expected to report? The consensus revenue estimate for Anteris Technologies Global is $2.75 million for Q3 2026. Anteris Technologies Global Earnings HeadlinesAnteris Technologies Global Corp. (NASDAQ:AVR) Stock Has Average Target Price of $14.00October 12 at 4:15 AM | americanbankingnews.comAvita Medical (NASDAQ:RCEL) and Anteris Technologies Global (NASDAQ:AVR) Head-To-Head ComparisonOctober 11 at 2:15 AM | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 14 at 1:00 AM | Profits Run (Ad)Anteris Technologies Global (NASDAQ:AVR) Stock: Insider L1 Capital Pty Ltd Buys 272,695 SharesOctober 10, 2026 | americanbankingnews.comAnteris (NASDAQ: AVR) investor L1 Capital adds shares to its stakeOctober 9, 2026 | americanbankingnews.comAnteris Technologies Expands Unquoted Equity Under Employee Incentive PlanOctober 8, 2026 | tipranks.comSee More Anteris Technologies Global Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anteris Technologies Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anteris Technologies Global and other key companies, straight to your email. Email Address About Anteris Technologies GlobalAnteris Technologies Global (NASDAQ:AVR) is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow. Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution. The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States. Anteris Technologies Global is led by Chief Executive Officer Wayne Patmore and trades on the Nasdaq under the symbol AVR.View Anteris Technologies Global ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
